All other indications: off-label / DVA / self-funded
Clinical Differentiation
Why neuronavigation matters clinically.
Standard rTMS uses the 5cm rule or 10-20 EEG system to estimate DLPFC location. Individual cortical anatomy varies by up to 20mm from population averages — meaning the intended target and actual stimulation site may differ substantially.
Neuronavigation uses the patient’s own structural MRI to map their unique anatomy, with real-time coil tracking throughout every session. This eliminates spatial error, ensures consistent placement, and allows individualised protocol selection based on anatomical findings.
Scalp landmark (5cm rule)
BrainAid Neuronavigated
Scalp landmark (5cm rule)
MRI-guided coordinates
Same target every patient
Individualised anatomy
No real-time tracking
Live coil monitoring
Treatment only
TMF holistic program
Limited reporting
Discharge summary to referrer
Evidence Base
What the research shows.
🧠 Treatment-Resistant Depression
A 4-week RCT (n=61) found remission rates comparable between rTMS and antidepressants (62%), with rTMS showing significantly greater reduction in Hamilton Depression Scale scores. Combining modalities may produce additive effects.
Chronic Pain & Fibromyalgia
⚡ Pain & Fibromyalgia
rTMS over the DLPFC produced greater analgesic effects vs tDCS in fibromyalgia RCT — 66.6% achieved ≥30% pain reduction. Neuropathic pain patients show differential response, supporting individualised targeting.
PubMed — peer reviewed
🧱 Cognitive Function
Meta-analysis of 19 studies (n=411) found rTMS produced positive memory effects (SMD=0.44), with superior efficacy in frontal regions — the primary neuronavigated target at BrainAid Clinics.
PubMed Central — peer reviewed
All citations from peer-reviewed sources. Off-label indications offered under psychiatrist oversight with informed consent. MBS 14217 applies to treatment-resistant depression only.
